Michael L. Lim

Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz, in Antiretroviral-Naive, HIV-1–Infected Adults: 48-Week Results From the ASSERT Study

Frank A. Post, Graeme Moyle, Hans Jürgen Stellbrink et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 217 citations

Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV‐Infected Antiretroviral‐Naive Subjects

Joel E. Gallant, Allan Rodríguez, Winkler G. Weinberg et al. · The Journal of Infectious Diseases · 2005 · 146 citations · Full text

Prevalence of Antiretroviral Drug Resistance and Resistance-Associated Mutations in Antiretroviral Therapy-Naïve HIV-Infected Individuals from 40 United States Cities

Lisa Ross, Michael L. Lim, Qiming Liao et al. · HIV Clinical Trials · 2007 · 102 citations · Full text

Coadministration of Lopinavir/Ritonavir and Phenytoin Results in Two-Way Drug Interaction Through Cytochrome P-450 Induction

Michael L. Lim, Sherene Min, Joseph J. Eron et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2004 · 94 citations

Molecular Pharmacology, Cytochrome P-450 Induction, Pharmacological Study +14

Long-Term Efficacy and Safety of Fosamprenavir plus Ritonavir Versus Lopinavir/Ritonavir in Combination with Abacavir/Lamivudine over 144 Weeks

Federico Pulido, Vicente Estrada, J.G. Baril et al. · HIV Clinical Trials · 2009 · 32 citations · Full text